8-K: Merus N.V. Reports Strong Interim Phase 2 Clinical Data for Petosemtamab Combination Therapy

Merus N.V. announced positive interim clinical data from its ongoing Phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab, showing high response rates and promising survival outcomes.

Summary

• Merus N.V. provided interim clinical data as of a February 27, 2025 data cutoff from its Phase 2 trial of petosemtamab in combination with pembrolizumab.
• The trial included 45 patients, with 43 patients evaluable for efficacy.
• The median follow-up for the 45 patients was 14.3 months.
• A confirmed overall response rate (ORR) of 63% (27/43 patients, 95% CI: 49-75) was observed in evaluable patients, including 6 complete responses and 21 partial responses.
• Responses were seen across PD-L1 levels (CPS 1-19: 47%; CPS > 20: 73%) and in HPV associated cancer (4 of 8 patients responded).
• Median progression-free survival (PFS) was 9 months (95% CI: 5.2-12.9).
• Median duration of response (DoR) and median overall survival (OS) were not reached at the time of data cutoff.
• The 12-month overall survival rate was 79% (30/43 censored).
• 14 patients, all responders, remained on treatment at the data cutoff.
• The combination therapy was generally well tolerated, with no significant overlapping toxicities with pembrolizumab.
• Treatment-emergent adverse events (TEAEs) occurred in all 45 patients, with Grade 3 TEAEs in 27 (60%) patients, and treatment-related Grade 3 TEAEs in 20 (44%) patients.
• Infusion-related reactions were reported in 38% of patients (all grades) and 7% (Grade 3), mainly during the first infusion and were resolved.

Sentiment

Score: 8

Explanation: The clinical data presented for petosemtamab in combination with pembrolizumab shows strong efficacy signals (high ORR, promising PFS and OS data) and a manageable safety profile, which is highly positive for a Phase 2 oncology asset and suggests significant potential.

Positives

• High confirmed overall response rate (ORR) of 63% in the efficacy evaluable population, including 6 complete responses.
• Responses observed across different PD-L1 levels, indicating broad applicability.
• Responses seen in HPV associated cancer, highlighting potential in specific patient subgroups.
• Promising median progression-free survival (PFS) of 9 months.
• Median duration of response (DoR) and median overall survival (OS) were not reached, suggesting durable responses and extended survival.
• High 12-month overall survival rate of 79%.
• The combination therapy was generally well tolerated with no significant overlapping toxicities with pembrolizumab.

Negatives

• Grade 3 treatment-emergent adverse events (TEAEs) occurred in 60% of patients, with 44% being treatment-related.
• Infusion-related reactions were reported in 38% of patients (all grades), with 7% being Grade 3.

Risks

• The Current Report contains forward-looking statements that are subject to known and unknown risks, uncertainties, assumptions, and other important factors, including those discussed under the caption Risk Factors in the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2025, which could cause actual results to differ materially.

Future Outlook

Merus N.V. expects to potentially share top-line interim readout results of one or both Phase 3 trials in 2026, indicating progression towards later-stage clinical development.

Management Comments

• "The Company expects to potentially share top line interim readout results of one or both phase 3 trials in 2026."

Industry Context

The positive interim Phase 2 data for petosemtamab, a bispecific antibody, in combination with pembrolizumab, a leading PD-1 inhibitor, positions Merus N.V. favorably in the competitive oncology landscape. Bispecific antibodies represent a growing class of therapeutics designed to target multiple pathways, potentially offering enhanced efficacy over monotherapies, especially in difficult-to-treat solid tumors. The observed high response rates and promising survival data suggest petosemtamab could be a significant addition to the immunotherapy arsenal.

Comparison to Industry Standards

• A confirmed overall response rate (ORR) of 63% in a Phase 2 oncology trial, particularly for a combination therapy, is generally considered strong and competitive, often exceeding ORRs seen with monotherapy PD-1 inhibitors like pembrolizumab in many advanced solid tumor settings.
• A median progression-free survival (PFS) of 9 months is a robust outcome for a Phase 2 study in advanced cancer, indicating a meaningful delay in disease progression.
• Median duration of response (DoR) and overall survival (OS) not being reached, coupled with a 79% 12-month OS rate, suggests durable responses and a significant survival benefit, which are critical indicators of a drug's potential clinical utility and often compare favorably to existing treatments for advanced solid tumors.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical trial results, which could increase the company's valuation and future revenue potential.
• Patients: Potential for a new, effective treatment option for solid tumors, particularly those with HPV-associated cancer.

Next Steps

• Potential sharing of top-line interim readout results of one or both Phase 3 trials in 2026.

Key Dates

Recommendation

Keywords

Merus, petosemtamab, pembrolizumab, bispecific antibody, oncology, cancer, clinical trial, Phase 2, overall response rate, progression-free survival, overall survival, adverse events, immunotherapy